Abstract Details

Title Evaluating the Clinical Utility of the Nine-hole Peg Test and SDMT in Stiff Person Syndrome Spectrum Disorders

Topic Autoimmune Neurology

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 2-008

Objective To assess the impact of stiff person syndrome spectrum disorders (SPSD) on the Nine-Hole Peg Test (9HPT) and Symbol Digit Modalities Test (SDMT).

Background SPSD are rare, neurological conditions primarily characterized by muscle rigidity and spasms, though other clinical features are increasingly recognized. Clinical measures are needed to assess different aspects of the disease, including upper limb and cognitive function. The 9HPT and SDMT are validated tools for assessing dexterity and information processing speed in other neurological populations. However, it is unclear whether these clinical tools may be useful in SPSD.

Design/Methods

Demographic, clinical, and functional data (9HPT and SDMT) were collected from patients with SPSD from a specialized center between 2024-2025. Associations between test outcomes and demographics, such as age and SPS type, were examined using multivariate analysis.

Results Seventeen SPSD patients were included; 65% had Classic SPS; 35% had SPS-plus. The mean 9HPT completion times were 35.27 seconds (dominant hand; SD: ±18.32) and 37.53 seconds (non-dominant hand; SD ±18.54). The mean SDMT score was 40.53 (SD: ±9.53). In a model adjusted for symptom duration and SPSD diagnosis, older age was significantly associated with lower SDMT scores (Coefficient = -0.3460; 95% CI: -0.6358, -0.0562). After adjusting for age and symptom duration, individuals with SPS-plus took, on average, 22.81 seconds longer (dominant hand; 95% CI: 4.67, 40.95) and 24.97 seconds longer (non-dominant hand; 95% CI: 6.54, 43.40) to complete the 9HPT compared to those with Classic SPS.

Conclusions This study highlights the potential use of 9HPT and SDMT in assessing some non-classical features of SPSD. Further studies are needed to assess whether such clinical tools can help monitor function over time.

Authors/Disclosures
Barrett Crawford PRESENTER	Mr. Crawford has nothing to disclose.
Hanyeh Afshar	Ms. Afshar has nothing to disclose.
Herbert Chen	Herbert Chen has nothing to disclose.
Jaida M. Appiah	Miss Appiah has nothing to disclose.
Scott D. Newsome, DO, FAAN (Johns Hopkins Hospital)	Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.

��ɫ��

��ɫ��